Těžké astma
Přehledové články
- Suchopár J, Prokeš M. Podkožně, nebo nitrožilně? Biologická léčba astmatu (staženo 35× )
- Eosinophils: changing perspectives in health and disease (staženo 65× )
Postery prezentované na AAAAI Annual Meeting, San Francisco, CA, USA, 22.–25. února, 2019
- Clinically meaningful improvements in asthma control questionnaire (ACQ) scores occur early, while asthma-related quality of life (AQLQ) scores continue to improve over 52 weeks, among patients with eosinophilic asthma receiving IV reslizumab (staženo 120× )
- High peripheral blood eosinophil levels are associated with low FEV1 reversibility in patients with severe eosinophilic asthma (staženo 223× )
- Evaluation of eosinophilic asthma patients without blood eosinophil (EOS) response to intravenous (IV) reslizumab in a post-hoc analysis of 52-week placebo-controlled Phase 3 studies (staženo 120× )
- A high proportion of exacerbation-prone patients with uncontrolled eosinophilic asthma receiving intravenous (IV) reslizumab experienced zero asthma exacerbations through 52 weeks of treatment (staženo 130× )
- Variability in absolute blood eosinophil (EOS) counts over 52 weeks in patients with inadequately controlled eosinophilic asthma receiving placebo in two duplicate clinical trials (staženo 116× )
Odborné texty
- Mukherjee M et al. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab (staženo 38× )
- Chanez P et al. Early decreases in blood eosinophil levels with reslizumab (staženo 66× )
- Monoklonální protilátky v léčbě prednison-dependentního astmatu (staženo 83× )
- Luis A. Pérez de Llano et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab (staženo 95× )
- Santus, Pierachille et al. Patients beliefs on intravenous and subcutaneous routes of administration of biologics for severe asthma treatment: A cross-sectional observational survey study (staženo 99× )
- Secondary loss of response to mepolizumab in severe eosinophilic asthma (staženo 142× )
- Novosad J, Krčmová I. Reslizumab. Remedia 2/2019 (staženo 195× )
- Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab (staženo 149× )
- Reslizumab v terapii pacientů s nedostatečně kontrolovaným eozinofilním astmatem (staženo 368× )
Prezentace
- Reslizumab v terapii neatopického eosinofilního astmatu
Alena Vlachová
